A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments

NCT05152472 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

110

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Gastrointestinal Stromal Tumor (GIST)
Locally Advanced Gastrointestinal Stromal Tumor (GIST)
Metastatic Gastrointestinal Stromal Tumor

Interventions

DRUG: Atezolizumab 1200 mg
DRUG: Imatinib 400 MG

Sponsor

Centre Leon Berard